{"title":"甘油三酯-葡萄糖指数与心力衰竭患者的预后:荟萃分析","authors":"Zhaoxia Yu, Wei Liu, Bo Li, Yutang Chen, Jian Li","doi":"10.17305/bb.2024.10559","DOIUrl":null,"url":null,"abstract":"<p><p>The triglyceride-glucose index (TyGI) is a novel indicator of insulin resistance, which has been associated with an increased risk of cardiovascular diseases. The aim of this meta-analysis was to determine the association between TyGI and the prognosis of patients with heart failure (HF). Cohort studies relevant to the aim of the meta-analysis were retrieved by searching electronic databases, including PubMed, Web of Science, and Embase. A random-effects model was used to combine the data, incorporating the influence of between-study heterogeneity. Twelve studies involving 20,639 patients with HF were included. Pooled results showed that compared to patients with the lowest category of TyGI at baseline, those with the highest TyGI index were associated with a higher risk of all-cause mortality during follow-up (relative risk [RR] 1.71, 95% confidence interval [CI] 1.46 - 2.00; P < 0.001; I² = 55%). Sensitivity analyses limited to studies after adjustment for confounding factors showed similar results (RR 1.89, 95% CI 1.67 - 2.21; P < 0.001; I² = 13%). Subsequent meta-analyses also showed that a high TyGI at baseline was related to the incidence of cardiovascular death (RR 1.87, 95% CI 1.42 - 2.47; P < 0.001; I² = 57%), HF rehospitalization (RR 1.33, 95% CI 1.04 - 1.69; P < 0.02; I² = 46%), and major adverse cardiovascular events (RR 1.69, 95% CI 1.39 - 2.06; P < 0.001; I² = 17%) during follow-up. In conclusion, a high TyGI may be associated with a poor clinical prognosis for patients with HF.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":" ","pages":"278-290"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734812/pdf/","citationCount":"0","resultStr":"{\"title\":\"Triglyceride-glucose index and the prognosis of patients with heart failure: A meta-analysis.\",\"authors\":\"Zhaoxia Yu, Wei Liu, Bo Li, Yutang Chen, Jian Li\",\"doi\":\"10.17305/bb.2024.10559\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The triglyceride-glucose index (TyGI) is a novel indicator of insulin resistance, which has been associated with an increased risk of cardiovascular diseases. The aim of this meta-analysis was to determine the association between TyGI and the prognosis of patients with heart failure (HF). Cohort studies relevant to the aim of the meta-analysis were retrieved by searching electronic databases, including PubMed, Web of Science, and Embase. A random-effects model was used to combine the data, incorporating the influence of between-study heterogeneity. Twelve studies involving 20,639 patients with HF were included. Pooled results showed that compared to patients with the lowest category of TyGI at baseline, those with the highest TyGI index were associated with a higher risk of all-cause mortality during follow-up (relative risk [RR] 1.71, 95% confidence interval [CI] 1.46 - 2.00; P < 0.001; I² = 55%). Sensitivity analyses limited to studies after adjustment for confounding factors showed similar results (RR 1.89, 95% CI 1.67 - 2.21; P < 0.001; I² = 13%). Subsequent meta-analyses also showed that a high TyGI at baseline was related to the incidence of cardiovascular death (RR 1.87, 95% CI 1.42 - 2.47; P < 0.001; I² = 57%), HF rehospitalization (RR 1.33, 95% CI 1.04 - 1.69; P < 0.02; I² = 46%), and major adverse cardiovascular events (RR 1.69, 95% CI 1.39 - 2.06; P < 0.001; I² = 17%) during follow-up. In conclusion, a high TyGI may be associated with a poor clinical prognosis for patients with HF.</p>\",\"PeriodicalId\":72398,\"journal\":{\"name\":\"Biomolecules & biomedicine\",\"volume\":\" \",\"pages\":\"278-290\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734812/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomolecules & biomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17305/bb.2024.10559\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"0\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomolecules & biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17305/bb.2024.10559","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
甘油三酯-葡萄糖指数(TyGI)是胰岛素抵抗的一个新指标,胰岛素抵抗与心血管疾病风险的增加有关。本荟萃分析旨在确定TyGI与心力衰竭(HF)患者预后之间的关系。通过搜索电子数据库,包括PubMed、Web of Science和Embase,检索了与荟萃分析目的相关的队列研究。采用随机效应模型合并数据,并考虑了研究间异质性的影响。共纳入了12项研究,涉及20639名心房颤动患者。汇总结果显示,与基线TyGI指数最低的患者相比,TyGI指数最高的患者在随访期间全因死亡的风险更高(相对风险[RR] 1.71,95% 置信区间[CI] 1.46 - 2.00;P < 0.001;I² = 55%)。仅限于对混杂因素进行调整后的研究的敏感性分析显示了类似的结果(RR 1.89,95% CI 1.67 - 2.21;P < 0.001;I² = 13%)。随后的荟萃分析还显示,基线时的高 TyGI 与心血管死亡发生率有关(RR 1.87,95% CI 1.42 - 2.47;P < 0.001; I² = 57%)、HF 再住院(RR 1.33, 95% CI 1.04 - 1.69; P < 0.02; I² = 46%)和随访期间主要不良心血管事件(RR 1.69, 95% CI 1.39 - 2.06; P < 0.001; I² = 17%)的发生率有关。总之,高TyGI可能与心房颤动患者不良的临床预后有关。
Triglyceride-glucose index and the prognosis of patients with heart failure: A meta-analysis.
The triglyceride-glucose index (TyGI) is a novel indicator of insulin resistance, which has been associated with an increased risk of cardiovascular diseases. The aim of this meta-analysis was to determine the association between TyGI and the prognosis of patients with heart failure (HF). Cohort studies relevant to the aim of the meta-analysis were retrieved by searching electronic databases, including PubMed, Web of Science, and Embase. A random-effects model was used to combine the data, incorporating the influence of between-study heterogeneity. Twelve studies involving 20,639 patients with HF were included. Pooled results showed that compared to patients with the lowest category of TyGI at baseline, those with the highest TyGI index were associated with a higher risk of all-cause mortality during follow-up (relative risk [RR] 1.71, 95% confidence interval [CI] 1.46 - 2.00; P < 0.001; I² = 55%). Sensitivity analyses limited to studies after adjustment for confounding factors showed similar results (RR 1.89, 95% CI 1.67 - 2.21; P < 0.001; I² = 13%). Subsequent meta-analyses also showed that a high TyGI at baseline was related to the incidence of cardiovascular death (RR 1.87, 95% CI 1.42 - 2.47; P < 0.001; I² = 57%), HF rehospitalization (RR 1.33, 95% CI 1.04 - 1.69; P < 0.02; I² = 46%), and major adverse cardiovascular events (RR 1.69, 95% CI 1.39 - 2.06; P < 0.001; I² = 17%) during follow-up. In conclusion, a high TyGI may be associated with a poor clinical prognosis for patients with HF.